Clinical Trials on Purpura, Thrombocytopenic in Argentina

Total 22 results

Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Italy, Greece, United Kingdom, Argentina, Poland, Austria
Bio Products Laboratory

Completed

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura

United States, India, Argentina
Novartis Pharmaceuticals

Recruiting

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Primary Immune Thrombocytopenia (ITP)

Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, United States, Argentina, Australia, United Kingdom, Poland
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
GlaxoSmithKline

Completed

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (PETIT2)

Idiopathic Thrombocytopenic Purpura

Thailand, Israel, Poland, Russian Federation, Spain, Germany, United Kingdom, Taiwan, Hong Kong, Czech Republic, Italy, United States, Argentina
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
Novartis Pharmaceuticals

Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

Primary Immune Thrombocytopenia (ITP)

China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
Novartis Pharmaceuticals

Recruiting

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (VAYHIT2)

Primary Immune Thrombocytopenia

United States, China, Germany, Spain, Singapore, Japan, Taiwan, Belgium, Italy, Czechia, Hungary, Malaysia, Korea, Republic of, Turkey, Argentina, Thailand, India, United Kingdom, France, Australia, Romania, Austria, Norway, Netherlands, Philippin...
Principia Biopharma, a Sanofi Company

Recruiting

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)

Immune Thrombocytopenia

United States, China, Argentina, Australia, Brazil, Canada, France, Hungary, Israel, Korea, Republic of, Mexico, Russian Federation, Singapore, Spain, Thailand, United Kingdom, Austria, Chile, Germany, Italy, Japan, Netherlands, Norway and more
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

Thrombocytopaenia

Spain, Taiwan, Bulgaria, United States, Argentina, Russian Federation, Germany, Korea, Republic of, Austria, India, Italy, United Kingdom, Poland, Romania, Ukraine, Hungary, Peru, Czech Republic, Mexico
Hospital General de Niños Pedro de Elizalde

Completed

Erythropoietin in Hemolytic Uremic Syndrome

Anemia | Hemolytic-Uremic Syndrome

Argentina
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
Novartis Pharmaceuticals

Completed

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (ASPIRE)

Thrombocytopaenia

United States, Belgium, Canada, Hong Kong, Argentina, Brazil, Czechia, Germany, Greece, Israel, Netherlands, Spain, Thailand, Hungary, Ireland, Italy, Mexico, Taiwan, Korea, Republic of, Poland, Russian Federation, Puerto Rico
Eisai Inc.

Completed

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Thrombocytopenia Associated With Liver Disease

United States, Italy, China, Taiwan, Spain, Belgium, Poland, Portugal, Canada, Korea, Republic of, Australia, Brazil, Chile, Austria, Germany, Hungary, France, Argentina, United Kingdom, Thailand
Eisai Inc.

Completed

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Thrombocytopenia Associated With Liver Disease

United States, China, Spain, Argentina, Belgium, Israel, Mexico, Romania, Japan, Brazil, Russian Federation, Germany, Italy, Czechia, Canada, Australia, France
Pfizer

Completed

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Neoplasms | Multiple Myeloma | Lymphoma, Malignant | Thrombocytopenia

United States, Argentina, Mexico
Inmunova S.A.
Chemo Research; KLIXAR; Linical; Crovelis

Not yet recruiting

Efficacy of INM004 in Children With STEC-HUS

Hemolytic-Uremic Syndrome

Argentina
Amgen

Active, not recruiting

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

Chemotherapy-induced Thrombocytopenia

United States, France, Austria, Hungary, Russian Federation, Romania, Spain, Turkey, Greece, Italy, Bulgaria, Canada, Portugal, Argentina, Poland, Mexico, Colombia, Peru, Brazil, Ukraine
Inmunova S.A.
Exeltis

Terminated

Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS

Hemolytic-Uremic Syndrome | Pediatric Kidney Disease | Bloody Diarrhea | STEC, Unspecified

Argentina
Inmunova S.A.
Linical Co., Ltd.; KLIXAR; PHV LATAM

Completed

A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS

Hemolytic-Uremic Syndrome | Pediatric Kidney Disease | Diarrhea-Associated Hemolytic Uremic Syndrome

Argentina
Amgen

Recruiting

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Chemotherapy-induced Thrombocytopenia

United States, Spain, Turkey, Argentina, Greece, Austria, Brazil, Bulgaria, Chile, Colombia, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Ukraine, Hungary
GlaxoSmithKline

Terminated

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures (ELEVATE)

Liver Diseases | HIV Infection | Thrombocytopenia | Hepatitis C Virus | HBV | NASH - Nonalcoholic Steatohepatitis | Human Immunodeficiency Virus | Chronic Liver Disease | HCV | Non-alcoholic Steatohepatitis | Hepatitis B Virus

United States, Spain, Taiwan, Italy, Belgium, France, Korea, Republic of, Canada, Russian Federation, Pakistan, Poland, India, Argentina

Clinical Trials on Purpura, Thrombocytopenic in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations